Comprehensive Analysis of 177Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination Schemes
Sebastian Patzke, Filippo Spriano, Katrine B. Melhus, Nicolas Munz, Alberto J. Arribas, Eugenio Gaudio, Roman Generalov, Ada H. V. Repetto‐Llamazares, Jostein Dahle, Francesco Bertoni
This paper evaluates the effectiveness of 177Lu-lilotomab satetraxetan in lymphoma cell lines, showing it is more effective in CD37-positive B-cell lymphomas and identifies potential biomarkers and synergistic combinations.
British Journal of Haematology · Sep 18, 2025Peer-reviewedCancer Biology